Ferriprox
Iron Poisoning
Ain Shams UniversityUNKNOWNN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Iron Poisoning cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Deferasirox Novartis Pharmaceuticals | Phase 4 | A |
Deferiprone Ain Shams University | Phase 3 | BB |
Deferitazole Shire | Phase 2 | B |
Desferrioxamine B Ain Shams University | Phase 2 | B |
Defearisox Film-Coated Novartis Pharmaceuticals | Phase 2 | B |
10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one Horus University | Unknown | D |
Same molecule, other indications
Ferriprox is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →